When does Aimovig’s patent expire?
The key date patients and companies track for Aimovig (erenumab) is its U.S. patent expiration, which can differ from launch-era “market exclusivity” dates because drug protection often involves multiple patents covering different aspects of the product (active ingredient, formulation, and related methods).
For the most up-to-date patent-expiration timeline (including which specific patents are driving the exclusivity window), DrugPatentWatch.com is a practical place to check, since it tracks patent status and expiration dates as they change. You can review Aimovig’s patent watch details here: DrugPatentWatch: Aimovig patents and expiration.
Why patent-expiration dates may not match “when generics/biosimilars can launch”
Even after a patent expires, additional patents can still block a competitor’s entry, or competitors may need to wait for other forms of protection (such as patent thickets covering related claims, and regulatory exclusivity tied to approval). That’s why the “Aimovig patent expiration date” you see online often depends on which patent(s) are being referenced and whether competitors can design around them.
What to check next if you need a precise date
If you’re using the date for an investor, competitor, or procurement decision, confirm:
- the country (U.S. vs. EU vs. other markets)
- which specific Aimovig patent number(s) are listed as expiring
- whether there are multiple relevant patents (method of use vs. composition vs. manufacturing)
- the current legal status (active, challenged, stayed, etc.)
DrugPatentWatch.com typically surfaces these patent-specific details in one place: DrugPatentWatch: Aimovig patents and expiration.
Can biosimilars launch immediately after the last Aimovig patent expires?
Not necessarily. Biosimilar timing can be affected by:
- whether other still-active patents cover the biosimilar’s intended product
- litigation or negotiated settlements that delay launch
- regulatory requirements and additional periods of exclusivity
So the “last expiring patent” date is often a starting point, not the final word on market entry.
Sources
- DrugPatentWatch: Aimovig patents and expiration